1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Jaguar Health Seeks Partner to Fund and Execute the Development & Commercialize of NP300

26 Nov 2024
Admin
News Article

Jaguar Health Seeks Partner to Fund and Execute the Development & Commercialize of NP300

Jaguar Health seeks partner to fund and execute the development & commercialize of NP300
Jaguar Health seeks partner to fund and execute the development & commercialize of NP300, a prescription drug candidate to treat general diarrhoea in dogs

Overview

Jaguar Health, Inc. (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhoea in dogs, in exchange for commercial rights to the product in the US.

About the Drug: NP300

NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhoea (CID) in dogs.
NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.

Words from the CMO: Jaguar

We look forward to evaluating NP300 for treatment of general, non-infectious diarrhoea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product,"" said David Sesin, PhD, Jaguar's chief manufacturing officer.
We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhoea in dogs as well. We estimate that US veterinarians see approximately six million annual cases of acute and chronic diarrhoea in dogs.

About Diarrhoea

Diarrhoea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there is currently no FDA-approved drug to treat canine diarrhoea.
According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of US households owning a dog in 2024.
Devastating diarrhoea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs.

About Jaguar Health, Inc.

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhoea, urgency, bowel incontinence, and cramping pain.